Sanofi agreed to buy U.S. biotech company Translate Bio in a $3.2 billion deal, as the French pharmaceuticals company bets on next-generation mRNA technology after setbacks in the Covid-19 vaccine race, confirming a Reuters exclusive report.
If you are not happy with the results below please do another search
50 search results for:
Novartis will launch a new phase three study to expand the use of Zolgensma – the world’s most expensive one-time therapy at $2.1 million per patient treatment – after the U.S. regulator lifted its restrictions.
The United States Food and Drugs Administration granted a priority review for Roche’s Tecentriq treatment for people suffering with early, non-small-cell lung cancer, the Swiss company said on Aug. 3.
Shares of Autolus Therapeutics were up in trading after the company announced an exclusive licensing agreement with Moderna to develop new messenger RNA therapeutics for cancer.
Abbott Laboratories will pay $160 million to resolve claims that two of the company’s units submitted false claims to Medicare by providing kickbacks to diabetes patients, including “free” or “no cost” glucose monitors, the U.S. Department of Justice said.
Ipsen, a global biopharmaceutical firm that specializes in neuroscience, oncology and rare diseases, partnered with Exicure, a clinical-stage biotech company that develops treatments for neurological, inflammatory and genetic disorders, to create new therapies for Angelman syndrome (AS) and Huntington’s disease (HD).
AbbVie’s Rinvoq continues to demonstrate the medicine’s clinical potential to become the heir-apparent to the company’s blockbuster drug Humira, which will lose patent protection in 2023. In the company’s second-quarter 2021 report, AbbVie touted advances Rinvoq made throughout the three months, including positive Phase III data in ulcerative colitis.
With a new wave of Covid-19 infections fueled by the Delta variant striking countries worldwide, disease experts are scrambling to learn whether the latest version of coronavirus is making people – mainly the unvaccinated – sicker than before.
Combining AstraZeneca’s Covid-19 vaccine with a second dose from either Pfizer-BioNTech or Moderna’s jab provides “good protection”, Denmark’s State Serum Institute said on Aug. 2.
Calcium—a full-service, independent healthcare marketing agency—named Maha Elashri as Executive Vice President and Chief Client Officer.